Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical ...

Globus Medical GMED has entered into a definitive agreement to acquire Nevro Corp. NVRO in an all-cash transaction valued at approximately $250 million. Under the terms of the agreement, unanimously ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Globus Medical (GMED – Research Report) and ...

In a report released today, Matt Miksic from Barclays maintained a Buy rating on Globus Medical (GMED – Research Report), with a price target ...

Buying $100 In GMED: If an investor had bought $100 of GMED stock 10 years ago, it would be worth $356.36 today based on a price of $86.88 for GMED at the time of writing.

Globus Medical (GMED) has agreed to buy Nevro (NVRO) through an all-cash deal valued at around $250M. Read more here.

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

Globus Medical (NYSE:GMED – Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The medical device company reported $0.83 EPS for the quarter, topping the ...

With a solid Zacks Rank and top-tier Growth and VGM Style Scores, GMED should be on investors' short list. Before you invest in Globus Medical, Inc. (GMED), want to know the best stocks to buy for ...

GMED boasts an average earnings surprise of 17.7%. Looking at cash flow, Globus Medical is expected to report cash flow growth of 72.4% this year; GMED has generated cash flow growth of 18.3% over the ...

KBC Group NV grew its position in shares of Globus Medical, Inc. (NYSE:GMED – Free Report) by 1.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities ...